STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Phone353-1232-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.78 billion
Profitability
Miscellaneous
Employees12,000
Next Earnings Date2/10/2020 (Estimated)
OptionableOptionable
Steris (NYSE:STE) Frequently Asked Questions
What is Steris' stock symbol?
Steris trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."
How often does Steris pay dividends? What is the dividend yield for Steris?
Steris announced a quarterly dividend on Monday, November 4th. Investors of record on Tuesday, November 26th will be paid a dividend of $0.37 per share on Friday, December 20th. This represents a $1.48 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date is Monday, November 25th. View Steris' Dividend History.
How were Steris' earnings last quarter?
Steris PLC (NYSE:STE) announced its quarterly earnings results on Monday, November, 4th. The medical equipment provider reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.26 by $0.06. The medical equipment provider had revenue of $736.84 million for the quarter, compared to the consensus estimate of $717.79 million. Steris had a return on equity of 16.15% and a net margin of 11.59%. The firm's quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.10 earnings per share. View Steris' Earnings History.
When is Steris' next earnings date?
What guidance has Steris issued on next quarter's earnings?
Steris updated its FY20 earnings guidance on Monday, November, 4th. The company provided earnings per share (EPS) guidance of $5.50-5.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.47.
What price target have analysts set for STE?
3 analysts have issued 12-month price targets for Steris' stock. Their forecasts range from $138.00 to $150.00. On average, they anticipate Steris' share price to reach $146.00 in the next year. This suggests that the stock has a possible downside of 5.3%. View Analyst Price Targets for Steris.
What is the consensus analysts' recommendation for Steris?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steris in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Steris.
What are Wall Street analysts saying about Steris stock?
Here are some recent quotes from research analysts about Steris stock:
- 1. According to Zacks Investment Research, "Over the past year, STERIS has been outperforming its industry.The company’s favorable underlying market trends along with new product and service offerings buoy optimism. Growth in free cash flow reserve is indicative of the company’s strong cash balance. The company raising its constant currency organic revenue growth expectations for fiscal 2019 is indicative of brighter prospects. Last December, STERIS announced a restructuring plan that involved shutting down of two manufacturing units along with product rationalization. It has also made certain divestments and organizational changes, which are expected to better align with its operations. However, currently customer consolidation scenario is raising concern, which is likely to adversely impact STERIS. The competitive landscape and weak cost reduction initiatives of STERIS continue to be causes of concern for the company." (4/30/2019)
- 2. JMP Securities analysts commented, "We reiterate our Market Outperform rating on STERIS and price target of $135 following the release of F3Q19 results. STE announced quarterly results following Monday’s close, and will hold its call at 10 a.m. ET today; we will look for more color on guidance, as well as revenue and earnings drivers at that time. Our $135 price target is based on 23-24x our CY20 EPS estimate of $5.70. Our multiple reflects a slight discount to a group of mid-to-high single-digit growing, mid- cap MedTech peers." (2/14/2019)
Has Steris been receiving favorable news coverage?
News coverage about STE stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Steris earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Steris.
Are investors shorting Steris?
Steris saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,430,000 shares, an increase of 27.7% from the December 15th total of 1,120,000 shares. Based on an average trading volume of 692,500 shares, the short-interest ratio is currently 2.1 days. Approximately 1.7% of the company's stock are sold short. View Steris' Current Options Chain.
Who are some of Steris' key competitors?
Some companies that are related to Steris include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).
What other stocks do shareholders of Steris own?
Who are Steris' key executives?
Steris' management team includes the folowing people:
- Mr. Walter M. Rosebrough Jr., CEO & Pres (Age 65)
- Mr. Michael J. Tokich, Sr. VP, CFO & Director (Age 50)
- Mr. Daniel A. Carestio, Chief Operating Officer (Age 46)
- Mr. John Adam Zangerle, Sr. VP, Gen. Counsel, Sec. & Director (Age 52)
- Dr. Adrian Vincent Coward, Sr. VP of Healthcare Specialty Services (Age 49)
Who are Steris' major shareholders?
Steris' stock is owned by a number of of institutional and retail investors. Top institutional investors include Boston Trust Walden Corp (0.19%), Gateway Investment Advisers LLC (0.07%), State of Alaska Department of Revenue (0.06%), West Coast Financial LLC (0.06%), PGGM Investments (0.05%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Steris stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard Martin Steeves, Sudhir K Pahwa, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View Institutional Ownership Trends for Steris.
Which institutional investors are selling Steris stock?
STE stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Cerebellum GP LLC, We Are One Seven LLC, West Coast Financial LLC, State of Alaska Department of Revenue, Raymond James Trust N.A. and IFP Advisors Inc. Company insiders that have sold Steris company stock in the last year include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard Martin Steeves and Walter M Rosebrough Jr. View Insider Buying and Selling for Steris.
Which institutional investors are buying Steris stock?
STE stock was purchased by a variety of institutional investors in the last quarter, including PGGM Investments, Gateway Investment Advisers LLC, Boston Trust Walden Corp, Assenagon Asset Management S.A., Nisa Investment Advisors LLC, Tocqueville Asset Management L.P., Park National Corp OH and First Hawaiian Bank. View Insider Buying and Selling for Steris.
How do I buy shares of Steris?
Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Steris' stock price today?
One share of STE stock can currently be purchased for approximately $154.13.
How big of a company is Steris?
Steris has a market capitalization of $13.07 billion and generates $2.78 billion in revenue each year. The medical equipment provider earns $304.05 million in net income (profit) each year or $4.89 on an earnings per share basis. Steris employs 12,000 workers across the globe.View Additional Information About Steris.
What is Steris' official website?
How can I contact Steris?
Steris' mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at 353-1232-2000 or via email at [email protected]
MarketBeat Community Rating for Steris (NYSE STE)
MarketBeat's community ratings are surveys of what our community members think about Steris and other stocks. Vote "Outperform" if you believe STE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STE will underperform the S&P 500 over the long term. You may vote once every thirty days.
